Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 3, 2004, Pages 386-390

  Xiong, Zheng Ping ^a   Yang, Shu Ren ^b   Liang, Zhao Yu ^a   Xiao, En Hua ^a   Yu, Xiao Ping ^a   Zhou, Shen Ke ^b   Zhang, Zi Shu ^b  

^a HUNAN CANCER HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Metastasis; Transcatheter arterial chemoembolization; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; FLUOROURACIL; IODINATED POPPYSEED OIL; MITOMYCIN C; VASCULOTROPIN;

ARTERY CATHETER; ARTICLE; BONE METASTASIS; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; PORTAL VEIN THROMBOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS;

ANOXIA; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; PROSPECTIVE STUDIES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4444369816     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Eriksson A, Cao R, Pawliuk R. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PIGF-1/VEGF heterodimers. Cancer Cell 2002;1:99-108.
2. Mao H, Yuan AL, Zhao MF, Metastasis of hepatocellular carcinoma induced by vascular endothelial growth factor. Chin J Hepatobiliary Surg 2001;7:34-36.
3. Passe TJ, Bluemke DA, Siegelman SS. Tumor angiogenesis: tutorial on implications for imaging. Radiology 1997;203:593-600.
4. Fidle I. The biology of human cancer metastasis. Acta Oncology 1991;30:669-675.
5. Folkman J. Clinical application of research on angiogenesis. N Engl J Med 1995;28:1757-1763.
6. Laughner E, Taghavi P, Chiles K. HER2 (neu) signaling increases the rate of hypoxia-inducible factor-1 a (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular Cellular Biology 2001; 21:3995-4004.
7. L'Allemain G. The hypoxia-inducible factor HIF as a new target in cancer research. Bull Cancer 2002;89:257-260.
8. Folkman J, Damore PA. Blood vessel formation: what is its molecular basis. Cell 1996;87:1153-1155.
9. Dhar DK, Naora H, Yamanoi A. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res 2002;22: 379-386.
10. Ruan G, Liu Y, Chen S. Inhibition of K562 cell growth and tumor angiogenesis in nude mice by antisense VEGF(121) cDNA transfection. Zhonghua Xue Ye Xue Za Zhi 2002;23:179-182.
11. Ikeda K, Kumada H, Saitoh S. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the cox proportional hazard model. Cancer 1991;68:2150-2154.
12. Hsu HC, Wei TC, Tsang YM. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer 1986;57:1184-1191.
13. Byung C, Song YH, Chung J. Association between vascular endothelial growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Cancer 2001;91:2386-2393.
14. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:1996-2003.
15. Wang F, Tian YH, Li L. XF inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002;34:165-170.
16. Li J, Wang WL, Liu B. Angiogenesis and apoptosis in human hepatocellular carcinoma. WCJD 1998;6:1057-1060.
17. Kenji JN, Masahito T, Ichinosuke H. Circulating vascular endothelial growth factor (vegf) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998;33:376-382.
18. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9:36-44.
19. Kane M, Furu T, Takena K. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989;10:98-102.
20. Xiong ZP, Yang SR, Xiao EH. Relation between vascular endothelial growth factor and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Chin J Oncol 2003;25:262-265.
21. Margolin K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep 2002;4:20-28.
22. Yoshiji H, Yoshii J, Ikenaka Y. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 2002;20:1227-1231.